Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET SCOPE
1.2.1              MARKETS COVERED
1.2.2              YEARS CONSIDERED FOR THE STUDY
1.3             CURRENCY
1.4             LIMITATIONS
1.5             STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.1.1              SECONDARY DATA
2.1.1.1            KEY DATA FROM SECONDARY SOURCES
2.1.2              PRIMARY DATA
2.1.2.1            KEY DATA FROM PRIMARY SOURCES
2.1.2.2            BREAKDOWN OF PRIMARY SOURCES
2.2             MARKET SIZE ESTIMATION
2.3             MARKET BREAKDOWN AND DATA TRIANGULATION
2.4             MARKET SHARE ESTIMATION
2.5             ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1             IMMUNOTHERAPY DRUGS MARKET OVERVIEW
4.2             NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE (2019)
4.3             GEOGRAPHIC SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET
4.4             PIPELINE OF PHASE 2/3 IMMUNOTHERAPY DRUGS

5.... MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
5.2.1              DRIVERS
5.2.1.1            INCREASING ADOPTION OF IMMUNOTHERAPY DRUGS OVER CONVENTIONAL TREATMENT REGIMENS
5.2.1.2            RISING PREVALENCE OF CANCER AND AUTOIMMUNE & INFECTIOUS DISEASES
5.2.1.3            INCREASING DEMAND FOR MONOCLONAL ANTIBODIES AND BIOSIMILARS

5.2.2              RESTRAINTS
5.2.2.1            TIMELINE ISSUES, SIDE-EFFECTS, AND MANUFACTURING COMPLEXITIES
5.2.2.2            HIGH ATTRITION RATE IN THE PRODUCT DEVELOPMENT CYCLE
5.2.3              OPPORTUNITIES
5.2.3.1            INCREASED DEMAND FOR PERSONALIZED MEDICINES
5.2.3.2            HIGH SCOPE FOR GROWTH IN EMERGING ECONOMIES
5.2.3.3            DEVELOPMENT OF AFFORDABLE NANOPARTICLES FOR DEPLOYING IMMUNOTHERAPIES
5.2.4              CHALLENGES
5.2.4.1            HIGH COST OF IMMUNOTHERAPY TREATMENT, REGIONAL DISPARITIES, AND LACK OF INSURANCE COVERAGE
5.2.4.2            SIDE-EFFECTS AND LOW EFFICACY OF IMMUNOTHERAPY DRUGS
5.2.4.3            LACK OF AWARENESS
5.2.4.4            DELAYS IN DIAGNOSIS AND TREATMENT
5.2.5              IMPACT OF THE COVID-19 PANDEMIC ON THE IMMUNOTHERAPY
DRUGS MARKET

6.... IMMUNOTHERAPY DRUGS MARKET, BY TYPE

6.1             INTRODUCTION
6.2             MONOCLONAL ANTIBODIES
6.2.1              MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019
6.3             CHECKPOINT INHIBITORS
6.3.1              CHECKPOINT INHIBITORS MARKET TO GROW OWING TO THEIR WIDE APPLICABILITY IN NUMEROUS CANCER TREATMENTS
6.4             INTERFERONS & INTERLEUKINS
6.4.1              INTERFERONS & INTERLEUKINS USE THE PATIENT’S IMMUNE SYSTEM, WHICH PROVIDES SIGNIFICANT BENEFITS
6.5             OTHER IMMUNOTHERAPIES

7.... IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA

7.1             INTRODUCTION
7.2             CANCER
7.2.1              MALIGNANT CANCERS.. 59
7.2.1.1            MALIGNANT CANCERS HELD THE LARGEST SHARE OF THE IMMUNOTHERAPY DRUGS MARKET IN 2019
7.2.2              BENIGN CANCERS
7.2.2.1            AVAILABILITY OF A RANGE OF DRUGS FOR BENIGN CANCER TREATMENT SUPPORTS MARKET GROWTH
7.3             AUTOIMMUNE & INFLAMMATORY DISEASES
7.3.1              STRONG DEMAND FOR IMMUNOTHERAPIES BOLSTERS MARKET GROWTH IN THIS SEGMENT
7.4             INFECTIOUS DISEASES
7.4.1              INCREASING PREVALENCE AND RISE IN R&D SUPPORT MARKET GROWTH
7.5             OTHER THERAPEUTIC AREAS

8.... IMMUNOTHERAPY DRUGS MARKET, BY END USER

8.1             INTRODUCTION
8.2             HOSPITALS
8.2.1              HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY DRUGS MARKET
8.3             CLINICS
8.3.1              CLINICS PROVIDE FOCUSED, PRIMARY-LEVEL CARE FOR PATIENTS AND CANNOT PROVIDE ADVANCED TREATMENTS.. 66
8.4             OTHER END USERS

9.... IMMUNOTHERAPY DRUGS MARKET, BY REGION

9.1             INTRODUCTION
9.2             NORTH AMERICA
9.2.1              US
9.2.1.1            US HOLDS THE LARGEST SHARE OF THE NORTH AMERICAN MARKET
9.2.2              CANADA
9.2.2.1            INCREASING PREVALENCE OF CANCER AND THE GROWING AVAILABILITY OF APPROVED IMMUNOTHERAPY DRUGS TO DRIVE MARKET GROWTH
9.3             EUROPE
9.3.1              UK
9.3.1.1            THE UK ACCOUNTS FOR THE LARGEST SHARE OF THE EUROPEAN MARKET
9.3.2              GERMANY
9.3.2.1            NEW LAW FOR BIOSIMILARS IN GERMANY TO DRIVE MARKET GROWTH
9.3.3              FRANCE
9.3.3.1            INITIATIVES BY LEADING PHARMA PLAYERS TO DRIVE THE FRENCH MARKET FOR IMMUNOTHERAPY DRUGS
9.3.4              ITALY
9.3.4.1            AVAILABILITY OF REIMBURSEMENT DRIVES THE MARKET IN ITALY
9.3.5              SPAIN
9.3.5.1            INCREASING INCIDENCES OF CANCER TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
9.3.6              REST OF EUROPE
9.4             ASIA PACIFIC
9.4.1              CHINA
9.4.1.1            RISING PREVALENCE OF CANCER AND OTHER INFECTIOUS DISEASES TO BOOST THE ADOPTION OF IMMUNOTHERAPY IN CHINA
9.4.2              JAPAN
9.4.2.1            UNIVERSAL HEALTH COVERAGE BOOSTS THE MARKET FOR IMMUNOTHERAPY DRUGS IN JAPAN
9.4.3              INDIA
9.4.3.1            HIGH NUMBER OF CANCER SPECIALTY CARE HOSPITALS TO SUPPORT MARKET GROWTH
9.4.4              AUSTRALIA
9.4.4.1            GOVERNMENT INITIATIVES TO PAVE THE WAY FOR THE DEVELOPMENT OF THE AUSTRALIAN IMMUNOTHERAPY DRUGS MARKET
9.4.5              REST OF ASIA PACIFIC
9.5             REST OF THE WORLD
9.5.1              MIDDLE EAST & AFRICA
9.5.1.1            INFRASTRUCTURAL GROWTH AND FAVORABLE SOCIOECONOMIC TRENDS WILL SUPPORT MARKET GROWTH IN THE MEA
9.5.2              BRAZIL
9.5.2.1            GOVERNMENT SUPPORT AND PLAYER INTEREST IN BRAZIL WILL DRIVE THE MARKET
9.5.3              REST OF LATIN AMERICA

10.. COMPETITIVE LANDSCAPE

10.1          INTRODUCTION
10.2          MARKET EVALUATION FRAMEWORK
10.3          REVENUE ANALYSIS OF TOP MARKET PLAYERS
10.4          COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)
10.4.1            STARS
10.4.2            EMERGING LEADERS.. 110
10.4.3            PERVASIVE COMPANIES
10.4.4            EMERGING COMPANIES
10.5          COMPETITIVE SCENARIO
10.5.1            KEY PARTNERSHIPS AND COLLABORATIONS
10.5.2            KEY PRODUCT LAUNCHES
10.5.3            KEY ACQUISITIONS.. 113
10.5.4            KEY EXPANSIONS

11. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
11.1          F. HOFFMANN-LA ROCHE
11.2          PFIZER
11.3          MERCK & CO
11.4          NOVARTIS INTERNATIONAL AG
11.5          JOHNSON & JOHNSON
11.6          SANOFI
11.7          GLAXOSMITHKLINE
11.8          ABBVIE
11.9          AMGEN
11.10        BOEHRINGER INGELHEIM
11.11        ASTRAZENECA
11.12        ELI LILLY AND COMPANY
11.13        IMMATICS BIOTECHNOLOGIES GMBH
11.14        GENMAB
11.15        BIONTECH SE
11.16        GILEAD SCIENCES
11.17        NBE THERAPEUTICS
11.18        TEVA PHARMACEUTICALS
11.19        BAYER AG
11.20        BRISTOL-MYERS SQUIBB
11.21        INCYTE CORPORATION
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

12.. APPENDIX

LIST OF TABLES

TABLE 1              GLOBAL CANCER INCIDENCE, 2018 VS. 2025
TABLE 2              GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005–2018
TABLE 3              COST OF KEYTRUDA, BY REGION (2018)
TABLE 4              CHECKPOINT INHIBITORS COVERED BY THE AUSTRALIAN PBS, AS OF JUNE 2019
TABLE 5              IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 6              THERAPEUTIC AREAS IN WHICH MONOCLONAL ANTIBODY
THERAPIES ARE APPROVED
TABLE 7              MONOCLONAL ANTIBODIES MARKET, BY REGION, 2018–2025 (USD BILLION)
TABLE 8              CHECKPOINT INHIBITORS MARKET, BY REGION, 2018–2025(USD BILLION)
TABLE 9              INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2014–2021 (USD BILLION)
TABLE 10            OTHER IMMUNOTHERAPIES MARKET, BY REGION, 2018-2025 (USD BILLION)
TABLE 11            IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 12            IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION,
2018–2025 (USD BILLION)
TABLE 13            IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 14            IMMUNOTHERAPY DRUGS MARKET FOR MALIGNANT CANCER, BY REGION,
2018–2025 (USD BILLION)
TABLE 15            IMMUNOTHERAPY DRUGS MARKET FOR BENIGN CANCER, BY REGION, 2018–2025 (USD BILLION)
TABLE 16            IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018–2025 (USD BILLION)
TABLE 17            IMMUNOTHERAPY DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD BILLION)
TABLE 18            IMMUNOTHERAPY DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2018–2025 (USD BILLION)
TABLE 19            IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
TABLE 20            IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION,
2018-2025 (USD BILLION)
TABLE 21            IMMUNOTHERAPY DRUGS MARKET FOR CLINICS, BY REGION,
2018–2025 (USD BILLION)
TABLE 22            IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION,
2018–2025 (USD BILLION)
TABLE 23            IMMUNOTHERAPY DRUGS MARKET , BY REGION, 2018–2025 (USD BILLION)
TABLE 24            NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION)
TABLE 25            NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,
2018–2025 (USD BILLION)
TABLE 26            NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 27            NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 28            NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 29            NEW CANCER CASES AND DEATHS IN THE US, BY TYPE, 2020
TABLE 30            US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 31            US: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 32            US: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 33            US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 34            CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 35            CANADA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 36            CANADA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 37            CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 38            EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION)
TABLE 39            EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 40            EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 41            EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 42            EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 43            UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 44            UK: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 45            UK: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 46            UK: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 47            GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,
2018–2025 (USD BILLION)
TABLE 48            GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 49            GERMANY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 50            GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 51            FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 52            FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 53            FRANCE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 54            FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 55            ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 56            ITALY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 57            ITALY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 58            ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 59            SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 60            SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 61            SPAIN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 62            SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 63            ROE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 64            ROE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 65            ROE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 66            ROE: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 67            APAC: INCREASE IN HEALTH EXPENDITURE, BY COUNTRY (USD PER CAPITA)
TABLE 68            APAC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION)
TABLE 69            APAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 70            APAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 71            APAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 72            APAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 73            CANCER CASES IN CHINA, 2018
TABLE 74            CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 75            CHINA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 76            CHINA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 77            CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 78            JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 79            JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 80            JAPAN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 81            JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 82            INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 83            INDIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 84            INDIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 85            INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 86            AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,
2018–2025 (USD BILLION)
TABLE 87            AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 88            AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 89            AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 90            ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 91            ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 92            ROAPAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 93            ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 94            ROW: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION)
TABLE 95            ROW: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 96            ROW: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 97            ROW: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 98            ROW: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 99            MEA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 100          MEA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 101          MEA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 102          MEA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 103          BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 104          BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 105          BRAZIL: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 106          BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 107          ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,
2018–2025 (USD BILLION)
TABLE 108          ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD BILLION)
TABLE 109          ROLATAM: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE,
2018–2025 (USD BILLION)
TABLE 110          ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY END USER,
2018–2025 (USD BILLION)
TABLE 111          PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2016–2019)
TABLE 112          PRODUCT LAUNCHES (2016–2019)
TABLE 113          ACQUISITIONS (2016–2019)
TABLE 114          EXPANSIONS (2016–2019)

FIGURE 1            RESEARCH DESIGN
FIGURE 2            PRIMARY SOURCES
FIGURE 3            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 4            MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5            ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE
FIGURE 6            DATA TRIANGULATION METHODOLOGY
FIGURE 7            IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY TYPE (2020)
FIGURE 8            IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY THERAPEUTIC AREA,
2020 VS. 2025 (USD BILLION)
FIGURE 9            IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY END USER,
2020 VS. 2025 (USD BILLION)
FIGURE 10          NORTH AMERICA DOMINATES THE MARKET, BUT APAC TO REGISTER THE HIGHEST GROWTH RATE  30
FIGURE 11          INCREASING ADOPTION OF IMMUNOTHERAPY DRUGS TO DRIVE THE MARKET
FIGURE 12          MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET IN 2019
FIGURE 13          ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE IMMUNOTHERAPY DRUGS MARKET FROM 2020 TO 2025
FIGURE 15          IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2019
FIGURE 16          NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIGURE 17          APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIGURE 18          MARKET EVALUATION FRAMEWORK: COLLABORATIVE EFFORT WAS A PROMINENT TARGET FOR MARKET COMPANIES
FIGURE 19          IMMUNOTHERAPY DRUGS MARKET IN 2019
FIGURE 20          COMPETITIVE LEADERSHIP MAPPING: IMMUNOTHERAPY DRUGS MARKET
FIGURE 21          F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019)
FIGURE 22          PFIZER: COMPANY SNAPSHOT (2019)
FIGURE 23          MERCK & CO: COMPANY SNAPSHOT (2019)
FIGURE 24          NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2019)
FIGURE 25          JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
FIGURE 26          SANOFI: COMPANY SNAPSHOT (2019)
FIGURE 27          GLAXOSMITHKLINE: COMPANY SNAPSHOT (2019)
FIGURE 28          ABBVIE: COMPANY SNAPSHOT (2019)
FIGURE 29          AMGEN: COMPANY SNAPSHOT (2019)
FIGURE 30          ASTRAZENECA: COMPANY SNAPSHOT (2019)
FIGURE 31          ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
FIGURE 32          GENMAB: COMPANY SNAPSHOT (2019)
FIGURE 33          BIONTECH SE: COMPANY SNAPSHOT (2019)
FIGURE 34          GILEAD SCIENCES: COMPANY SNAPSHOT (2019)

当レポートのプレスリリースは発行されておりません。